Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.72 |
| ▸ | HTR2B | P41595 | 3/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115308 | 0.94 | HTR2C (0.70) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL468604 | 0.84 | HTR2C (1.00) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL3226116 | 0.82 | HTR2C (0.97) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL3413391 | 0.81 | HTR2C (0.62) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL7370885 | 0.81 | HTR2C (0.62) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL12481728 | 0.77 | HTR2C (0.57) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| Butane SCHEMBL8573679 | 0.77 | HTR2C (0.85) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL8002464 | 0.77 | ADRA1A (0.66) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL9577659 | 0.76 | HTR2C (0.56) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL3213611 | 0.76 | HTR2C (0.79) | HTR2CHTR2BADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342301-A1 | ANTIBODY-DRUG CONJUGATES | MC SAF (FR) | 2024-10-17 | — | — | US | disclosed |
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | MC SAF (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-4181964-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | Mc SAF (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-2920166-B1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2920166-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | Array Biopharma, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-7838676-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | SHBG, SERPINA6, F13B | HTR2C 4480/4885HTR2B 3883/4885ADRA1D 2589/4885 |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | HTR2C 1478/4885HTR2B 1112/4885ADRA1D 716/4885 |
| US-20240342301-A1 | ANTIBODY-DRUG CONJUGATES | FCGRT, FCGR3B, FCGR2A | HTR2C 4065/4885HTR2B 4016/4885ADRA1D 4483/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | HTR2C 485/4885HTR2B 206/4885ADRA1D 31/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | HTR2C 1478/4885HTR2B 1112/4885ADRA1D 716/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | HTR2C 1478/4885HTR2B 1112/4885ADRA1D 716/4885 |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | HTR2C 1478/4885HTR2B 1112/4885ADRA1D 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.